Skip to main content Skip to search Skip to main navigation

ICH: ICH Q3C(R8) Guideline for Residual Solvents contains new PDEs

ICH published the revised version (Step 4) of the ICH Q3C(R8) Guideline on Impurities: Guideline for Residual Solvents on 22 April 2021.

The Permitted Daily Exposure (PDE) values for the following substances were added:  

  • 2-Methyltetrahydrofuran (50 mg/day) 
  • Cyclopentyl methyl ether (15 mg/day)  
  • Tertiary butyl alcohol (35 mg/day) 

The PDE values were developed by the relevant Expert Working Group (EWG). On 25 March 2020, ICH already published the document for public consultation under Step 2 (we reported). The values proposed then have been adopted as final and the Step 4 version has not been changed compared to the draft document. This allows implementation to take place in the ICH regions. This ICH process, which is conducted under "Step 5", concludes the revision. 

Toxicity details:  

  • Methyltetrahydrofuran was found to be non-genotoxic in a mutation assay with bacteria, human lymphocytes and rats. No data are available on carcinogenicity. Reproductive toxicity and repeated-dose toxicity were not observed. The product was classified in solvent class 3.  
  • For cyclopentyl methyl ether, no toxicity in humans was found. Likewise, no genotoxic potential was found. Again, no data are available on carcinogenicity. No statements could be made on reproductive and developmental toxicity on the basis of data available to date. The product was classified as a class 2 solvent.  
  • For tertiary butyl alcohol, no genotoxicity was found either. The data on carcinogenicity do not allow any precise conclusions to be drawn with regard to the effect on humans, while changes in the renal tubules were found in rats. No precise statements could be made on reproductive toxicity either, but moderate transient systemic toxicity was found in rats. The product was classified as a class 2 solvent.  

In a revision process, further PDE values are to be gradually added as new toxicological data for solvents become known. 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

IPEC: Stability Guide for Excipients has been Updated

IPEC: Stability Guide for Excipients has been Updated

The IPEC Stability Guide for Pharmaceutical Excipients has been updated and is now available as version 3 (2026), as announced on the IPEC (International Pharmaceutical Excipients Council) website.

Read more
EU: “Forever Chemicals” in a Conflict of Interests

EU: “Forever Chemicals” in a Conflict of Interests

On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.

Read more
How is the Effectiveness of CAPAs Verified?

How is the Effectiveness of CAPAs Verified?

Here's the answer:
Read more
Handover of Computerised Systems to the Operating Department

Handover of Computerised Systems to the Operating Department

The GMP-compliant handover of computerised systems to operations is a critical step in the Computer System Validation (CSV) lifecycle. Beyond go-live and hypercare, clearly defined responsibilities, comprehensive documentation and well-trained personnel are essential to maintaining a validated state throughout routine operation.
Read more
APIC: Publishes Updated “How to Do” Document for GDP for Active Pharmaceutical Ingredients

APIC: Publishes Updated “How to Do” Document for GDP for Active Pharmaceutical Ingredients

The Active Pharmaceutical Ingredients Committee (APIC) has published Version 3 of the document “GDP for APIs: How to Do” (June 2026) on its website. The document provides practical guidance on implementing Good Distribution Practice for active pharmaceutical ingredients.

Read more
TGA: Seeks Feedback on Planned Adoption of 11 International Scientific Guidelines

TGA: Seeks Feedback on Planned Adoption of 11 International Scientific Guidelines

Australia's regulatory authority, the TGA (Therapeutic Goods Administration), pursues a strategy of aligning its regulatory approaches as closely as possible with comparable international standards. These include the regulatory requirements of the EU, the FDA and the ICH. In this context, around 370 international scientific guidelines have already been adopted.

Read more
Previous
Next